Vista Partners Updates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $4.50
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwire) -- 01/31/13 -- announced today that it has updated coverage on (NYSE MKT: ANX) ("ADVENTRX" or "ANX") with a twelve month target price of $4.50. Ross Silver, Principal Analyst at Vista Partners, stated, "ANX announced that it has initiated patient recruitment in its pivotal Phase 3 clinical study of ANX-188 (purified poloxamer 188) in sickle cell disease which is a major milestone." Mr. Silver continued, "There has been a tremendous amount of partnering and M&A activity in Sickle Cell Disease. In September 2012, was granted an exclusive option to acquire , following the successful completion of a Phase 2 clinical study in patients with sickle cell disease. Including upfront, acquisition and milestone payments. completed a partnering deal with , for their investigational compound GMI-1070 currently in Phase 2 development for the treatment of vaso-occlusive crisis associated with sickle cell disease, with a potential value of approximately $340M." Mr. Silver concludes, "The aforementioned pharma deals would seem to serve as valuation benchmarks and notably both of the companies are behind ADVENTRX in terms of clinical progress. ANX currently trades at a negative enterprise value, the cash value per share was approximately $0.84 at the end of the third quarter, a discount of approximately 20% from the current share price."
To download a FREE copy of the research report, please visit and click the "download research" icon to gain access to the report.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking.
Please follow Vista Partners on (at)VistaPResearch & at Vista-Partners to receive updates, thoughts and ideas about our coverage universe of companies.
Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website or click .
Contact:
John Heerdink
877.215.4813
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 31.01.2013 - 14:15 Uhr
Sprache: Deutsch
News-ID 225005
Anzahl Zeichen: 7338
contact information:
Town:
SAN FRANCISCO, CA
Kategorie:
Commercial & Investment Banking
Diese Pressemitteilung wurde bisher 292 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Vista Partners Updates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $4.50"
steht unter der journalistisch-redaktionellen Verantwortung von
Vista Partners LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
